Dr. Gupta discusses avelumab first-line maintenance treatment for advanced urothelial carcinoma

No CxM-negative patients had findings of a recurrent tumor on a follow-up cystoscopy.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

The investigators used data from the National Inpatient Sample database to identify 5280 patients with non-metastatic bladder cancer who underwent RC from 2016 to 2019.

“I wouldn't be surprised if we have spotty distribution areas of concern for the next several years,” says Sam S. Chang MD, MBA, on the latest episode of the UT podcast Speaking of Urology.

Avelumab is approved by the FDA as a maintenance therapy for patients with locally advanced/metastatic urothelial carcinoma that has not progressed with first-line, platinum-based chemotherapy.

At 6 months, high-grade RFS in the BCG group was 76%, compared with 92% in the gemcitabine and docetaxel group.